Advertisement

Development and commercialization of a treatment for inflammatory diseases developed by Infinity Pharmaceuticals Inc. is moving to Purdue Pharmaceutical Products LP and Mundipharma International Corp. Ltd., as part of an alliance formed by the companies in 2008.

Purdue and Mundipharma will exercise the rights to Infinity’s fatty acid amide hydrolase (FAAH) program, with plans for Purdue to begin Phase 2 studies next year of Infinity’s FAAH inhibitor, which is intended to better enable the body to respond favorably to anti-inflammatory treatment.

SOURCE

Advertisement
Advertisement